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Summary A drug-eluting stent was implanted at the culprit lesion in a 65-year-old man with
acute coronary syndrome. Nine days after the procedure, he suffered stent thrombosis, and
a bare-metal stent was subsequently implanted. Twelve days after this second procedure, a
follow-up angiogram showed a newly emerged thrombus at the site of stent implantation.
Although the patient had continued dual anti-platelet therapy with aspirin and clopidogrelpolymorphism;
Clopidogrel;
Poor responsiveness
since the ﬁrst procedure, platelet optical aggregation test showed no inhibition of aggregation.
Further, genetic analysis revealed him to be homozygous for the CYP2C19*2 polymorphism. This
case suggests that the mechanism of stent thrombosis, while multi-factorial, is affected greatly
by crossover of poor responsiveness to clopidogrel due to the CYP2C19*2 polymorphism.
© 2011 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
iIntroductionDual anti-platelet therapy with aspirin and clopidogrel is
routinely administered after coronary stent implantation
∗ Corresponding author. Tel.: +81 799 22 1200;
fax: +81 799 24 5704.
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doi:10.1016/j.jccase.2011.02.003ncluding drug-eluting stents (DES) to stave off thrombotic
vents. Despite this treatment, however, many patients
ith DESs still experience thrombotic and ischemic events.
everal recent studies have shown that poor or non-
esponsiveness to clopidogrel is strongly associated with
tent thrombosis and poor clinical outcome in patients with
ESs [1,2].
Genetic polymorphisms may play a pivotal role in deter-
ining patient responsiveness to clopidogrel. In particular,
Published by Elsevier Ltd. All rights reserved.
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Figure 1 (a) A coronary angiogram showed severe stenosis in the left main trunk (LMT). (b) A 3.5× 23-mm stent (PromusTM, Boston
Scientiﬁc Corporation, Natick, MA, USA) was implanted at 12 atm, and we performed kissing balloon dilatation. (c) After kissing
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aalloon dilation, plaque prolapse appeared in the proximal site
laque prolapsed in the 6—8 o’clock direction (plaque prolapse
he 2C19*2 allelic variant (681A allele) polymorphism of
ytochrome P450 (CYP) is a common genetic functional
ariant believed to be an important contributor to the
ide inter-individual variability in the anti-platelet effect
f clopidogrel [3—6].
Here, we report a patient with the CYP2C19*2 polymor-
hism who suffered from repeated intra-stent thrombus
ormation, including stent thrombosis, caused by poor
esponsiveness to clopidogrel due to this polymorphism and
emonstrated by the serial change in platelet aggregation
est.
ase report
65-year-old Japanese man, who had reported experiencing
hest pain when exerting himself on 26 April 2010, experi-
nced severe chest pain and dyspnea on 28 April and was
dmitted to the emergency unit of our hospital. A electro-
ardiogram demonstrated ST segment elevation in aVR, aVL,
nd V1—V4 leads and depression in the II, III, aVF, V5, and
6 leads, and an echocardiogram showed severe hypoki-
esis in the anterior and lateral regions. Laboratory tests
evealed the following: white blood cell count, 11,700/l;
spirate aminotransferase, 43 IU/l; lactate dehydrogenase,
71mequiv./l; creatine kinase, 313mequiv./l; C-reactive
rotein, 0.13mg/dl; glucose, 122mg/dl, and troponin I,
.890mg/ml. Given that the patient’s oxygen saturation was
7% even after being placed on 7 l of oxygen administered
I
p
te LMT stent. (d) Intravascular ultrasound examination revealed
ated by white arrow).
ia a reservoir mask, we promptly performed intubation
nd supported him via a mechanical ventilator. Emergent
oronary angiography (CAG) showed a severe stenosis in
he left main trunk (LMT), but no signiﬁcant stenosis in
he right coronary artery (Fig. 1a). Because the patient’s
emodynamic status was unstable, we promptly inserted
n intra-aortic balloon pump (IABP) to stabilize it. We then
erformed percutaneous coronary intervention (PCI) for the
MT to the left anterior descending artery (LAD) with balloon
nﬂation, implanted a 3.5× 23-mm DES (PromusTM, Boston
cientiﬁc Corporation, Natick, MA, USA) guided by intravas-
ular ultrasound (IVUS; EagleEyeTM; Volcano Therapeutic
nc., Tokyo, Japan) and performed kissing balloon dilatation
Fig. 1b). Given that the angiogram showed plaque prolapse
n stent site (Fig. 1c and d), we performed post-dilatation
ith a 3.5× 15-mm balloon (HiryuTM, Terumo, Tokyo, Japan)
p to only 6 atm to compress prolapsed intra-stent plaques,
s high-pressure additional ballooning might induce much
arger plaque prolapse. We conﬁrmed reduction of the pro-
apse area using CAG and IVUS (minimum stent area was
.0mm2), and then ﬁnished the procedure.
A loading dose of clopidogrel (300mg) was administered
o the patient immediately after the procedure, after which
e received a maintenance dose of clopidogrel (75mg/day)
nd aspirin (100mg/day). The patient was weaned from the
ABP after seven days and the ventilator after eight.
However, nine days after the initial procedure, the
atient complained of severe chest pain, and the elec-
rocardiogram showed ST segment elevation in aVR, aVL,
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Figure 2 (a) A coronary angiogram showed stent occlusion in the stent site. (b) After aspiration of the thrombus, intravascular
ultrasound revealed intra-stent thrombus localized in the left main trunk (LMT) site and malapposition (*) at the stent proximal
edge. (c) A 4.0× 20-mm bare-metal stent (LiberteTM, Boston Scientiﬁc Corporation, Natick, MA, USA) was deployed at the LMT,
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dilatation.
V1—V4 leads, and depression in II, III, aVF, V5, 6 leads.
We performed an emergent angiogram on suspicion of sub-
acute stent thrombosis, and the second CAG showed total
occlusion of the stent site in the LMT (Fig. 2a). After
IABP insertion, we aspirated the thrombus using a thrombi-
extraction catheter (Thrombuster III GRTM; Kaneka, Osaka,
Japan). After coronary ﬂow was regained to Thrombolysis In
Myocardial Infarction 2 ﬂow, we performed IVUS and found
an intra-stent thrombus and strut mal-apposition at the
proximal edge of the stent, which had not been noted after
the ﬁrst procedure (Fig. 2b). We implanted a 4.0× 20-mm
bare-metal stent (BMS; LiberteTM; Boston Scientiﬁc Corpora-
tion) to cover the mal-apposition at the proximal edge of the
previously inserted stent without crossing over the ostium of
circumﬂex and performed post-ballooning with a 5.0× 10-
mm non-compliant balloon (HiryuTM) at 16 atm (Fig. 2c).
Subsequent IVUS revealed good dilatation and apposition of
the BMS. And also, a ﬁnal angiogram showed good luminal
dilatation (Fig. 2d).
Two days after the second PCI, the patient’s hemodynam-
ics stabilized, and he was weaned off of IABP. Ten days later,
we performed a follow-up CAG (Fig. 3a), which revealed a
newly emerged mobile thrombus in the middle of the stent
site. We then aspirated the thrombus using a 5-Fr catheter
TM(Hertrail , Terumo) and conﬁrmed size reduction via IVUS
and CAG (Fig. 3b).
We initially suspected that the repeated intra-stent
thrombus formation, including stent thrombosis, was due
r
t
e
diant balloon up to 16 atm. (d) A ﬁnal angiogram showed good
o heparin-induced thrombocytopenia (HIT). However, no
IT-associated immunoglobulins were detected. We then
uspected poor responsiveness to clopidogrel as the cause
f stent thrombosis and conducted a platelet aggregation
est and genetic examination. Results of the aggregation
est showed normal aggregation with 3g ADP (Fig. 4a),
udged as a non-responder to dual antiplatelet therapy,
nd the genetic examination showed the patient to be
omozygous for the CYP2C19*2 polymorphism. We changed
he antiplatelet regimen to aspirin 100mg + ticlopidine
00mg+ cilostazol 200mg/day. A follow-up platelet aggre-
ation test conducted after starting this new regimen
howed good inhibition with 3g ADP (Fig. 4b), and 23 days
fter the second PCI, follow-up CAG showed disappearance
f the stent thrombus.
enetic analysis of patients with DES
hrombosis (experience at two hospitals)
rom January 2009 to April 2010, 532 patients were
mplanted DESs at Hyogo Prefectural Awaji Hospital and
obe University Hospital. Of these 532 patients, six pre-
ented with DES thrombosis. On examining the genetic test
esults of ﬁve patients with stent thrombosis, we found
hat three were homozygous for CYP2C19*2, one was het-
rozygous, and one was a non-carrier. Details of these are
escribed in Table 1.
e126 M. Iwasaki et al.
Figure 3 (a) Twelve days after the second percutaneous coronary intervention, an intra-stent thrombus was noted in the middle
of the stent (white arrow). (b) After switching the patient from clopidogrel to ticlopidine, the thrombus disappeared.
Table 1 The characteristic data of the patients with drug-eluting stent thrombus.
Case Age Sex Duration after PCI Stent size Risk factors of stent
thrombosis
CYP2C19*2
polymorphism
1 65 M 8 days EES 2.5mm× 23mm ACS, stent
undersizing,
uncovered vulnerable
plaque
Homozygous
2 56 M 5 days SES 2.5mm× 23mm,
2.5mm× 15mm
ACS, low ejection
fraction, stent
under-expansion
Homozygous
3 66 M 5 days PES 3.0mm× 20mm Low ejection
fraction,
malapposition
Heterozygous
4 75 F 2 months SES 3.0mm× 28mm,
2.5mm× 18mm
Crush stent (2 stents) Homozygous
5 71 M 5 days PES 2.5mm× 20mm Under expansion,
post rotablator
Non carrier
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iACS, acute coronary syndrome; F, female; M, male; PCI, percu
paclitaxel-eluting stent; SES, sirolimus-eluting stent.
iscussion
ere, we reported a patient with the CYP2C19*2 polymor-
hism who suffered from repeated intra-stent thrombus
ormation, including stent thrombosis, caused by poor
esponsiveness to clopidogrel. Our observation suggests that
enetics-induced poor responsiveness to clopidogrel may
ffect intra-stent thrombus formation and, when combined
ith other risk factors, increase a patient’s likelihood of
eveloping stent thrombosis.While a rare complication, stent thrombosis is a catas-
rophic adverse event. Previous reports highlighted several
actors associated with an increased risk of stent throm-
osis, including the details of the PCI procedure (stent
t
s
t
oous coronary intervention; EES, everolimus-eluting stent; PES,
al-apposition or under-expansion, number of implanted
tents, stent length, persistent slow coronary blood ﬂow,
resence of dissections), patient and lesion characteris-
ics, stent design, and premature cessation of anti-platelet
rugs [7,8]. In this case, several considerable risk factors
or stent thrombosis were observed: namely acute coronary
yndrome, an implanted DES, relatively undersized stent in
omparison with the vessel size, and uncovered vulnerable
laque. In this case, however, despite the fact that the min-
mal stent area was over 7mm2 after the ﬁrst PCI, and that
hese risks had been almost completely resolved after the
econd PCI, the patient still experienced sub-acute stent
hrombosis, and an intra-stent thrombus formed repeatedly
ver a short period. Because the patient continued to show
Repeated intra-stent thrombus formation due to clopidogrel resi
Figure 4 Aggregation test stimulated with 3mol adenosine
5′ diphosphate (ADP). (a) Platelet second-wave aggregation
was not inhibited when receiving clopidogrel. (b) Second-wave
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Referencesaggregation was well inhibited when receiving ticlopidine and
cilostazol (black arrow).
normal platelet aggregation despite receiving dual anti-
platelet therapy with aspirin and clopidogrel, we switched
the clopidogrel for ticlopidine and added cilostazol, sus-
pecting clopidogrel resistance. After this change, platelet
aggregation was inhibited, and no more intra-stent thrombi
formed. This ﬁnding suggests that stent thrombosis occurs
mainly due to technical factors, but may be affected greatly
by the crossover of poor responsiveness to clopidogrel.
Recently, genetic polymorphisms have been implicated
as causes of clopidogrel resistance. The CYP2C19*2 poly-
morphism is a common genetic functional variant and has
been the target of much investigation as the cause of
impaired platelet inhibition in patients receiving clopido-
grel [3—6]. This polymorphism has also been associated
with high on-treatment platelet reactivity after administra-
tion of clopidogrel [4]. Other studies have demonstrated a
signiﬁcant association between CYP2C19*2 carriers and an
increased risk of stent thrombosis following coronary stent
implantation [5]. Although the incidence of the CYP2C19*2
polymorphism is markedly higher in Asian populations,
including Japanese, than Western populations, few studies
have investigated the association between stent thrombosis
and CYP2C19*2 polymorphisms among Japanese. At our two
institutions, we encountered six patients with DES thrombo-
sis, all receiving dual anti-platelet therapy with clopidogrel.
Of the six patients, ﬁve patients were genotyped, and, four
(80%) subsequently found to be *2 carriers (three homozy-
gous and one heterozygous). Although this analysis was smallstance associated with genetic polymorphism e127
nd nonrandomized and each patient had several risk fac-
ors for stent thrombosis, the incidence of stent thrombosis
ppeared to be ostensibly higher in CYP2C19*2 carriers than
n non-carriers. Therefore, while this may not be the only
ause of stent thrombosis, our data suggest that having
CYP2C19 polymorphism may be strongly associated with
tent thrombosis through poor responsiveness to clopidogrel
n the Japanese population, while we do not consider the
YP2C19 polymorphism alone to be a main cause of stent
hrombosis.
Despite the incidence of the CYP2C19*2 polymorphism
eing markedly higher in the Japanese population than
estern populations, the incidence of stent thrombosis
mong Japanese is reported to be rare as compared to
estern patients [9,10]. We hypothesize the following two
easons for this discrepancy: First, IVUS is routinely used
s an adequate and efﬁcient procedure in many hospitals
n Japan. Therefore, technical risk factors such as under-
ized stents, mal-apposition, and dissection may be largely
voided, and the inﬂuence of poor responsiveness to clopi-
ogrel may be reduced by guarding against these technical
actors. Second, the loading (300mg) and the mainte-
ance dosages (75mg/day) of clopidogrel may be large for
apanese patients compared with Western patients, due to
ifferences in body size. For intermediate metabolizers, the
urrent dosage of clopidogrel may be sufﬁcient to achieve an
nti-platelet response. Several reports have suggested the
eed for weight-adjusted dosing of clopidogrel, as underdos-
ng appears to be a primary predictor of failed dosing [11].
We previously demonstrated a signiﬁcantly higher
ncidence of intra-stent thrombus in *2 carriers than in
on-carriers (52.4% vs. 15.5%) using optical coherence
omography analysis six months after sirolimus-eluting
tent implantation [12]. In this case intra-stent thrombus
ecognized in the third angiogram did not induce stent
hrombosis. We therefore believe that patients with
YP2C19*2 polymorphisms have a high probability of devel-
ping subclinical intra-stent thrombi and are likely to have
eveloped stent thrombosis in the presence of additional
isk factors for stent thrombosis.
Finally, in this case, a platelet aggregation test showed
ood inhibition with 3g ADP and follow-up CAG showed dis-
ppearance of the stent thrombus after starting a new reg-
men of anti-platelet therapy (aspirin 100mg + ticlopidine
00mg+ cilostazol 200mg). Cilostazol reversibly inhibits
latelet aggregation via its selective inhibition of phospho-
iesterase type 3 and results in increased cyclic adenosine
onophosphate in platelets [13]. This unique antithrom-
otic property inhibits phosphorylation of vasodilatator
timulated phosphoprotein, which is an active site of clopi-
ogrel. Jeong et al. demonstrated that adjunctive cilostazol
ith normal-dose clopidogrel intensiﬁes platelet inhibition
s compared with a high maintenance dose of clopidogrel
14]. Therefore, we consider adjunctive cilostazol could be
n alternative regimen to achieve an enhanced platelet inhi-
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